Name: 'Fast Money' traders Karen Finerman and Tim Seymour unveil their 2026 trader acronyms
Uploaded: 2026-01-13T23:11:44+00:00
Duration: 301 s

Speakers

Karen Finerman — CEO, Metropolitan Capital Advisors; Fast Money trader

Tim Seymour — Seymour Asset Management, Fast Money Trader

Summary

Karen Finerman and Tim Seymour unveil their 2026 trader acronyms on Fast Money. Finerman presents B-DANG: Boeing, Dow, Amazon, Novo Nordisk, and Structure Therapeutics. Seymour presents TIMBO: Target, IEFA/international equities, Melco, Biogen, and Oracle. Both traders explain bullish theses for each name, emphasizing turnarounds, valuation, pipeline catalysts, and international outperformance.

Karen Finerman's B-DANG includes Boeing, Dow, Amazon, Novo Nordisk, and Structure Therapeutics.
Tim Seymour's TIMBO includes Target, an international ETF, Melco, Biogen, and Oracle.
Finerman sees Boeing improving cash flow, Amazon cheap versus Walmart/AWS, and Novo/Structure advantaged in oral GLP-1.
Seymour sees Target as a turnaround, expects international outperformance, and likes Melco on China normalization.
Seymour chose Biogen for its Phase 2/3 pipeline catalysts and Oracle as a beaten-up, world-class name.
The segment is a year-ahead stock-picking exercise using mnemonic acronyms.

Ideas

Karen Finerman CEO, Metropolitan Capital Advisors; Fast Money trader 1:09

Boeing cash flow positive coming up.

Finerman is bullish on Boeing again, saying she likes it for all the familiar reasons and expects positive cash flow in the coming period.

Karen Finerman CEO, Metropolitan Capital Advisors; Fast Money trader 1:13

Dow rebound after disappointing year.

She thinks Dow was disappointing last year, up only mildly when it should have done much better, and expects the company to get its act together this year.

Karen Finerman CEO, Metropolitan Capital Advisors; Fast Money trader 1:18

Amazon too cheap versus Walmart and AWS.

Amazon looks too cheap relative to Walmart's valuation and considering the value of AWS, so she likes the stock.

Karen Finerman CEO, Metropolitan Capital Advisors; Fast Money trader 1:25

Novo leads oral GLP-1 race.

She loves that Novo Nordisk is now in front and ahead in the oral GLP-1 space.

Karen Finerman CEO, Metropolitan Capital Advisors; Fast Money trader 1:38

Structure is oral GLP-1 takeover target.

She sees Structure Therapeutics as a takeover target because it has land in the oral GLP-1 space, which is undergoing a land grab.

Tim Seymour Seymour Asset Management, Fast Money Trader 3:03

Target turnaround with management and segment changes.

Seymour calls Target a change-of-character turnaround: a bombed-out name that has turned the corner, has management changes, and is moving into different segments.

Tim Seymour Seymour Asset Management, Fast Money Trader 3:14

International equities outperform and stay attractive.

He favors his international ETF, saying international has outperformed and already done it again this year, and he thinks it will continue to be a place investors want to be.

Tim Seymour Seymour Asset Management, Fast Money Trader 3:25

Melco rebound on China normalization.

He is bullish on Melco, the Macau gaming company: gross gaming revenues have underperformed and the stock pulled back 35%, but he thinks China is starting to normalize.

Tim Seymour Seymour Asset Management, Fast Money Trader 3:46

Biogen pipeline catalysts drive 2026 performance.

He chose Biogen over broad biotech because it has at least 5 to 6 drugs in Phase 2 or 3, with major 2026 catalysts including Lacombe, and he sees big performance after a bottom.

Tim Seymour Seymour Asset Management, Fast Money Trader 4:03

Oracle beaten up, valuation ignores AI contracts.

He does not love Oracle here but included it because it is so beaten up, is a world-class company, and its valuation does not reflect potential AI contracts.

'Fast Money' traders Karen Finerman and Tim Seymour unveil their 2026 trader acronyms

Summary

Ideas

Up Next